AstraZeneca PLC (ZEG)
XETRA Stock Exchange · Germany · prices in EUR · close of 15 Oct 2026
Key indicators
| Last close | EUR 160.70 |
|---|---|
| 52-week range | 139.20 – 166.30 |
| Return, 1 month / 3 months | +0.0% / +0.5% |
| Return, 1 year / 3 years | +10.4% / +31.4% |
| Trend | Uptrend |
| RSI (14) | 79 |
| Volatility (1 year) | 18.9% |
| Worst drawdown (1 year) | -10.8% |
| Average daily value traded | 0.00M EUR |
| Dividend yield | 2.1% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
AstraZeneca is a pharmaceutical company that researches, develops and makes prescription medicines. Its products treat cancer, heart and blood vessel disease, breathing conditions such as asthma, and diabetes, among other illnesses. The company serves patients and healthcare providers through hospitals, clinics and pharmacies in many countries. It is based in Cambridge in the United Kingdom, and it also has substantial operations in Sweden, where part of its heritage lies.
The shares are listed on the XETRA Stock Exchange in Germany under the code ZEG, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
AstraZeneca PLC (ZEG) trades on the XETRA Stock Exchange in Germany. It last closed at EUR 160.70 on 15 October 2026.
Its price-based Market X-Ray is 62 out of 100 (a fair price profile), ranking 227 of 701 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 10.4% and over the last three months it rose 0.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on XETRA Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 3.2% | ||
| From 52-week high | -2.7% | ||
| Momentum | 61 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 0.5% | ||
| 6-month return | – | ||
| 12-month return, skipping the last month | 10.4% | ||
| Stability (higher is calmer) | 96 · Strong | Calmer than most: low volatility and shallow drawdowns. | |
| Volatility, 1 year (lower is calmer) | 18.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -10.8% | ||
| Liquidity | 0 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M EUR | ||
| Zero-volume days | 100.0% | ||
| Income | 45 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.1% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Stability (higher is calmer): Calmer than most: low volatility and shallow drawdowns.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +0.5% |
| 6 months | – |
| 1 year | +10.4% |
| 3 years | +31.4% |
| 5 years | +68.0% |
Signals
| 50-day / 200-day average | 160.70 / 155.65 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.00 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Aug 2026 | GBP 0.9424 |
| 19 Feb 2026 | GBP 1.8433 |
| 7 Aug 2025 | GBP 0.8864 |
| 20 Feb 2025 | GBP 1.9416 |
| 8 Aug 2024 | GBP 0.8968 |
| 22 Feb 2024 | GBP 1.8029 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on XETRA Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.